FIG. 4.

Normal body pharmacokinetic and dosimetric efficacy. Each line indicates a different pharmaceutical: cefazolin, k₁₂:k₂₁ = 0.91; diazepam, k₁₂:k₂₁ = 2.69; sulpiride, k₁₂:k₂₁ = 5.09; quinidine, k₁₂:k₂₁ = 11.89; doxorubicin, k₁₂:k₂₁ = 17.59. The slope of each line indicates the sensitivity that each pharmaceutical possesses with respect to k₄₃:k₃₄. The relatively low k₁₂:k₂₁ ratio of cefazonlin, 0.91, is most sensitive to a change in k₄₃:k₃₄ compared with the other pharmaceuticals of interest. Its normal body pharmacokinetics are more conducive to an efficacious targeted radionuclide therapy.